TD Cowen analyst Phil Nadeau reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "On Friday, Revuforj (revumenib) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE